Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | MTOR | P42345 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.57 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.57 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.57 |
| ▸ | GMNN | O75496 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.57 |
| ▸ | THPO | P40225 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | HBB | P68871 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2579580 | 0.95 | LMNA (0.62) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL5953706 | 0.95 | LMNA (0.62) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL5953287 | 0.95 | LMNA (0.62) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL18512948 | 0.95 | LMNA (0.62) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL6297856 | 0.95 | LMNA (0.62) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL5697581 | 0.95 | LMNA (0.62) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL41572 | 0.95 | LMNA (0.62) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL14441083 | 0.95 | LMNA (0.62) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL14929291 | 0.95 | LMNA (0.62) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL15630246 | 0.95 | LMNA (0.62) | LMNAMTORALDH1A1TP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250565-A1 | OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES | ALPHA ANOMERIC SAS (FR) | 2025-08-07 | — | — | US | disclosed |
| US-20240343752-A1 | NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM | UNIV BERN (CH) | 2024-10-17 | — | — | US | disclosed |
| US-11919922-B2 | Bicyclic nucleosides and oligomers prepared therefrom | UNIVERSITAT BERN (CH) | 2024-03-05 | — | — | US | disclosed |
| CN-110023322-B | Novel bicyclic nucleosides and oligomers prepared therefrom | 伯尔尼大学 | 2023-10-27 | — | — | CN | disclosed |
| US-20230132377-A9 | OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES | ALPHA ANOMERIC SAS (FR) | 2023-04-27 | — | — | US | disclosed |
| US-20220089632-A1 | NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM | UNIV BERN (CH) | 2022-03-24 | — | — | US | disclosed |
| US-20220017898-A1 | OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES | ALPHA ANOMERIC SAS (FR) | 2022-01-20 | — | — | US | disclosed |
| US-11028117-B2 | Bicyclic nucleosides and oligomers prepared therefrom | Universität Bern (CH) | 2021-06-08 | — | — | US | disclosed |
| EP-3790968-A1 | OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES | Alpha Anomeric SAS (FR) | 2021-03-17 | — | — | EP | disclosed |
| CN-112424352-A | Oligonucleotide conjugates comprising 7 '-5' -alpha-anomeric bicyclic sugar nucleosides | 阿尔法阿诺麦里克公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20010006801-A1 | BASE-MODIFIED ENZYMATIC NUCLEIC ACID | USMAN NASSIM (US) | 2001-07-05 | — | — | US | disclosed |
| US-5891684-A | RIBOZYMES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-04-06 | — | — | US | disclosed |
| US-5879938-A | RIBOZYME WITH INCREASED ACTIVITY BY SUBSTITUTION OF MODIFIED NUCLEOTIDE INTO SUBSTRATE BINDING ARM OR CATALYTIC CORE | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-03-09 | — | — | US | disclosed |
| US-5767263-A | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-06-16 | — | — | US | disclosed |
| EP-0799313-A2 | METHOD AND REAGENT FOR TREATMENT OF ARTHRITIC CONDITIONS, INDUCTION OF GRAFT TOLERANCE AND REVERSAL OF IMMUNE RESPONSES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-10-08 | — | — | EP | disclosed |
| US-5672501-A | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-09-30 | — | — | US | disclosed |
| US-5672511-A | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-09-30 | — | — | US | disclosed |
| EP-0728204-A1 | BASE-MODIFIED ENZYMATIC NUCLEIC ACID | RIBOZYME PHARMACEUTICALS, INC. (US) | 1996-08-28 | — | — | EP | disclosed |
| WO-1996018736-A2 | METHOD AND REAGENT FOR TREATMENT OF ARTHRITIC CONDITIONS, INDUCTION OF GRAFT TOLERANCE AND REVERSAL OF IMMUNE RESPONSES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1996-06-20 | — | — | WO | disclosed |
| WO-1995013378-A1 | BASE-MODIFIED ENZYMATIC NUCLEIC ACID | RIBOZYME PHARMACEUTICALS, INC. (US) | 1995-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089632-A1 | NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM | RRM2, PRPF31, PYGM | LMNA 309/4885MTOR 1634/4885ALDH1A1 3285/4885 |
| US-11028117-B2 | Bicyclic nucleosides and oligomers prepared therefrom | RRM2, NUDT1, REV1 | LMNA 275/4885MTOR 1438/4885ALDH1A1 2881/4885 |
| US-20240343752-A1 | NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM | RRM2, RRM2B, REV1 | LMNA 305/4885MTOR 2034/4885ALDH1A1 2607/4885 |
| US-11919922-B2 | Bicyclic nucleosides and oligomers prepared therefrom | RRM2, REV1, NUDT1 | LMNA 268/4885MTOR 1647/4885ALDH1A1 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.